201 results match your criteria: "Australian Centre for Oral Oncology Research & Education[Affiliation]"
Cancer Epidemiol Biomarkers Prev
April 2024
Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
J Am Coll Cardiol
December 2023
Department of Health Metrics Sciences, Institute for Health Metrics and Evaluation, School of Medicine, University of Washington, Seattle, Washington, USA; Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA. Electronic address:
Int J Pharm
December 2023
Centre for Pharmaceutical Innovation (CPI), UniSA Clinical & Health Sciences, University of South Australia, South Australia, Australia. Electronic address:
Self-emulsifying drug delivery systems (i.e. SEDDS, SMEDDS and SNEDDS) are widely employed as solubility and bioavailability enhancing formulation strategies for poorly water-soluble drugs.
View Article and Find Full Text PDFNat Med
January 2024
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
JAMA Oncol
October 2023
Department of Preventive and Social Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Pilot Feasibility Stud
July 2023
Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Level 7, Harold Stokes Building, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Background: Self-reported penicillin allergies are highly prevalent in hospitalised patients and are associated with poor health and health service outcomes. Critically ill patients have historically been underrepresented in prospective delabelling studies in part due to concerns around clinical stability and reliability of penicillin skin testing. Allergy assessment tools exist to identify low-risk penicillin allergy phenotypes and facilitate direct oral challenge delabelling.
View Article and Find Full Text PDFJ Biophotonics
September 2023
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, Australia.
Hyperspectral and multispectral imaging of cell and tissue autofluorescence is an emerging technology in which fluorescence imaging is applied to biological materials across multiple spectral channels. This produces a stack of images where each matched pixel contains information about the sample's spectral properties at that location. This allows precise collection of molecularly specific data from a broad range of native fluorophores.
View Article and Find Full Text PDFPLoS One
May 2023
Faculty of Health, Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), University of Technology Sydney, Ultimo, New South Wales, Australia.
Anorexia is experienced by most people with lung cancer during the course of their disease and treatment. Anorexia reduces response to chemotherapy and the ability of patients to cope with, and complete their treatment leading to greater morbidity, poorer prognosis and outcomes. Despite the significant importance of cancer-related anorexia, current therapies are limited, have marginal benefits and unwarranted side effects.
View Article and Find Full Text PDFJ Antimicrob Chemother
July 2023
Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Background: Urinary tract infections (UTIs) due to MDR organisms are increasingly common. The lack of paediatric data on efficacious antibiotics makes UTI treatment particularly challenging. Data on the efficacy of fosfomycin use for UTI in children are variable.
View Article and Find Full Text PDFInt J Mol Sci
May 2023
School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide 5005, Australia.
J Oral Pathol Med
July 2023
Australian Centre for Oral Oncology Research & Education, Perth, Western Australia, Australia.
Lancet Oncol
April 2023
Monash University, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report the planned primary overall survival analysis, with the aim of defining the benefit of enzalutamide treatment in different prognostic subgroups (synchronous and metachronous high-volume or low-volume disease) and in those who received concurrent docetaxel.
Methods: ENZAMET is an international, open-label, randomised, phase 3 trial conducted at 83 sites (including clinics, hospitals, and university centres) in Australia, Canada, Ireland, New Zealand, the UK, and the USA.
Nat Commun
March 2023
Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
In heterogeneous head and neck cancer (HNC), subtype-specific treatment regimens are currently missing. An integrated analysis of patient HNC subtypes using single-cell sequencing and proteome profiles reveals an epithelial-mesenchymal transition (EMT) signature within the epithelial cancer-cell population. The EMT signature coincides with PI3K/mTOR inactivation in the mesenchymal subtype.
View Article and Find Full Text PDFJ Oral Pathol Med
July 2023
Australian Centre for Oral Oncology Research and Education, Nedlands, Western Australia, Australia.
Background: Dysregulation of the hypoxia-aerobic system has been postulated in various malignancies. Nonetheless, the contribution of hypoxia to oral carcinogenesis is yet to be elucidated. Understanding this mechanism is important for improving diagnostic tools and targeted therapies.
View Article and Find Full Text PDFN Engl J Med
March 2023
From the Department of Dermatology, University of Sydney at Royal Prince Alfred Hospital (N.C.A., V.A.S., A.D.G., A.C.C., D.L.D.), the NHMRC (National Health and Medical Research Council) Clinical Trials Centre, University of Sydney (A.J.M., R.E.), and the Department of Renal Medicine (S.J.C.) and the A.W. Morrow Gastroenterology and Liver Centre (D.G.B.), Royal Prince Alfred Hospital, Camperdown, NSW, the Skin Health Institute, Carlton, VIC (A.H.C., K.J.A., R.B.D., B.P.M., T.K.), the Department of Dermatology, University of Sydney at Westmead Hospital, Westmead, NSW (P.F.-P.), the Department of Dermatology, the Alfred Hospital (D.G., A.D.G., J.N.), the Department of Anatomical Pathology, Alfred Health (C.M.), and the Department of Anatomical Pathology, Royal Melbourne Hospital (A. Landgren), Melbourne, VIC, the Department of Dermatology, Royal Adelaide Hospital (S.S., C.A., B.W., B.S.), and South Australia Pathology (J.I.), Adelaide, SA, the Department of Dermatology, University of New South Wales at St. Vincent's Hospital (V.L.P., N.D.R., T.S.), NSW Health Pathology (C.A.M., R.A.S.), the Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital (C.A.M., R.A.S.), Faculty of Medicine and Health (R.A.S., J.L.V., D.G.B.), Melanoma Institute Australia (R.A.S., D.L.D.), Charles Perkins Centre (R.A.S., S.J.C.), and the Centre for Medical Psychology and Evidence-Based Decision-Making (H.M.D., J.L.V.), University of Sydney, and the Liver Immunology Program, the Centenary Institute, University of Sydney and Royal Prince Alfred Hospital (D.G.B.), Sydney, the Departments of Dermatology (L.A.B., H.S., A.D., A.T., H.G., H.A.E.) and Pathology (A.D.), Sunshine Coast University Hospital, Griffith University Medical School (L.A.B.), and the School of Health and Behavioural Sciences, University of the Sunshine Coast (A.D.), Birtinya, QLD, the Department of Dermatology, University of Sydney at Royal North Shore Hospital, St. Leonards, NSW (A. Lim), the Department of Dermatology, Royal Melbourne Hospital, Parkville, VIC (E.U., B.J.D., Y.K., K.S., Z.M.L.), the Dermatology Research Centre, Diamantina Institute, the University of Queensland (H.S., H.A.E.), and the Department of Dermatology, Princess Alexandra Hospital (H.A.E.), Woolloongabba, QLD, Melbourne Pathology, Sonic Healthcare, Collingwood, VIC (S.P.), Southern.IML Pathology, Sonic Healthcare, Coniston, NSW (A. Lochhead), Wollongong Hospital, Wollongong, NSW (A. Lochhead), the School of Medicine, University of Queensland, Herston (A.T.), and the Department of Medicine, Concord Clinical School, University of Sydney, and Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW (J.L.V.) - all in Australia.
Background: Immunosuppressed organ-transplant recipients have an increased incidence of, and mortality from, skin cancer. Nicotinamide (vitamin B) enhances the repair of ultraviolet (UV) radiation-induced DNA damage, reduces the cutaneous immunosuppressive effects of UV radiation, and reduces the incidence of keratinocyte cancers (including squamous-cell and basal-cell carcinomas) and actinic keratoses among high-risk immunocompetent patients. Whether oral nicotinamide is useful for skin-cancer chemoprevention in organ-transplant recipients is unclear.
View Article and Find Full Text PDFInt J Mol Sci
February 2023
UWA Dental School, The University of Western Australia, Nedlands, WA 6009, Australia.
This study aimed to develop an in vitro three-dimensional (3D) cell culture model of oral carcinogenesis for the rapid, scalable testing of chemotherapeutic agents. Spheroids of normal (HOK) and dysplastic (DOK) human oral keratinocytes were cultured and treated with 4-nitroquinoline-1-oxide (4NQO). A 3D invasion assay using Matrigel was performed to validate the model.
View Article and Find Full Text PDFCancer
April 2023
Western Sydney University Medical School, Campbelltown, New South Wales, Australia.
Background: Senaparib is a novel, selective poly(ADP-ribose) polymerase-1/2 inhibitor with strong antitumor activity in preclinical studies. This first-in-human, phase 1, dose-escalation study examined the safety and preliminary efficacy of senaparib in patients with advanced solid tumors.
Methods: Patients with advanced solid tumors were enrolled from three centers in Australia, using a conventional 3 + 3 design.
Adv Mater
March 2023
Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, 200011, P. R. China.
Although immunotherapy has revolutionized oncotherapy, only ≈15% of head and neck squamous cell carcinoma (HNSCC) patients benefit from the current therapies. An immunosuppressive tumor microenvironment (TME) and dysregulation of the polycomb ring finger oncogene BMI1 are potential reasons for the failure. Herein, to promote immunotherapeutic efficacy against HNSCC, an injectable nanocomposite hydrogel is developed with a polymer framework (PLGA-PEG-PLGA) that is loaded with both imiquimod encapsulated CaCO nanoparticles (RC) and cancer cell membrane (CCM)-coated mesoporous silica nanoparticles containing a peptide-based proteolysis-targeting chimeras (PROTAC) for BMI1 and paclitaxel (PepM@PacC).
View Article and Find Full Text PDFObjective: To evaluate a new protocol of risk stratification and early discharge for children with febrile neutropenia (FN).
Design: Prospective service evaluation from 17 April 2020 to 16 April 2021.
Setting: 13 specialist centres in the UK.
Bone
March 2023
Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated research in Musculoskeletal Ageing, Department of Oncology & Metabolism, University of Sheffield, Sheffield, United Kingdom; Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom. Electronic address:
The relative contributions of factors such as muscle strength, falls risk and low bone mineral density (BMD) to increased fracture risk in Parkinson's Disease (PD) were examined in an analysis of 5212 community-dwelling women age 75 years or more recruited to a randomised, double-blind, placebo-controlled study of the oral bisphosphonate, clodronate. Similar number of PD and non-PD subjects received treatment. Each participant had measurements of hip and forearm BMD, muscle strength (hand grip strength and maximum isometric quadriceps strength), ability in the sit-to-stand test, and postural stability.
View Article and Find Full Text PDFBMC Med
December 2022
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Future Oncol
November 2022
Saint-Louis Hospital & Université Paris Cité, Paris, 75010, France.
Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on underlying disease pathophysiology. Murine double minute 2 (MDM2), a negative regulator of p53, is overexpressed in circulating malignant CD34 MF cells.
View Article and Find Full Text PDFBackground: More than 3 billion people do not have access to clean energy and primarily use solid fuels to cook. Use of solid fuels generates household air pollution, which was associated with more than 2 million deaths in 2019. Although local patterns in cooking vary systematically, subnational trends in use of solid fuels have yet to be comprehensively analysed.
View Article and Find Full Text PDFBlood
October 2022
Translational Medicine, Bristol Myers Squibb, Summit, NJ.
The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials.gov identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC) who were not candidates for hematopoietic stem cell transplantation. Eligible patients were randomized 1:1 to Oral-AZA 300 mg or placebo for 14 days per 28-day cycle.
View Article and Find Full Text PDFCurr Opin Support Palliat Care
September 2022
Department of Hematology.
Purpose Of Review: For decades, clinical decision making and practice has been largely informed by data generated through randomized clinical trials (RCTs). By design, RCTs are highly restricted in both scope and scale, resulting in narrow indications and iterative advances in clinical practice. With the transition to electronic health records, there are now endless opportunities to utilize these 'real world' data (RWD) to make more substantive advances in our understanding that are, by nature, more applicable to reality.
View Article and Find Full Text PDF